Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, has announced its participation in virtual events during November and December 2021. Key highlights include:
- Credit Suisse Healthcare Conference on November 8, featuring CEO Jim Dentzer.
- Jefferies Global Healthcare Conference on November 18, where Dentzer will also present.
- B. Riley Oncology Panel on December 1, featuring Robert Martell.
Live webcasts can be viewed on Curis's website, with archived replays available for 90 days.
Curis, Inc. (NASDAQ: CRIS) announced new preclinical data for its IRAK4 inhibitor, CA-4948, at the AACR-NCI-EORTC Virtual Conference. The data demonstrates CA-4948's potential in treating non-Hodgkin's lymphoma, acute myeloid leukemia, and myelodysplastic syndromes. Notably, the research indicates CA-4948 may synergize with existing therapies and effectively cross the blood-brain barrier, enhancing survival rates in aggressive CNS lymphoma. This supports ongoing Phase 1 clinical trials aimed at examining its effectiveness in various hematologic cancers.
Curis, Inc. (NASDAQ: CRIS) announced on October 1, 2021, that its Compensation Committee approved inducement stock options for five new employees, totaling 106,350 shares. Each option has a 10-year term and an exercise price set at the closing stock price on the grant date. Vested options will occur over four years, beginning with 25% vesting after the first year of employment. These grants are part of Curis's strategy to attract talent as it continues to develop innovative cancer therapies, including various ongoing clinical trials for its product candidates.
Curis, a biotechnology company focused on cancer therapeutics, announced the participation of CEO James Dentzer in two upcoming virtual healthcare conferences. The Morgan Stanley Virtual Global Healthcare Conference is set for September 10, 2021, at 11:00 a.m. ET, followed by the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20 a.m. ET. Presentations will be available via live webcast and later as a replay on Curis' investor website. Curis is developing key cancer drugs, including CA-4948, which is in clinical trials for non-Hodgkin's lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) reported its Q2 2021 financial results, showing a net loss of $10.8 million ($0.12/share), compared to a loss of $6.7 million in Q2 2020. Revenues slightly decreased to $2.3 million, primarily from royalties. The company continues to advance its pipeline, notably the IRAK4 inhibitor CA-4948, demonstrating positive data in clinical trials for AML/MDS patients. Operating expenses rose to $12.9 million due to increased R&D costs. Curis holds $160.7 million in cash, sufficient to fund operations into 2024.
Curis, Inc. (NASDAQ: CRIS) announced it will release its second quarter 2021 financial results on August 3, 2021, after US market close. A conference call will be held at 4:30 pm ET the same day. The company is focused on developing innovative therapeutics for cancer treatment, including collaborations on several clinical trials. Notably, CA-4948 is currently in Phase 1/2 trials for non-Hodgkin lymphoma and has received Orphan Drug Designation for acute myeloid leukemia from the FDA.
Curis, Inc. (NASDAQ: CRIS) announced on July 1, 2021, the approval of inducement stock options for 259,550 shares to fifteen new employees. These stock options have an exercise price equal to the closing price on the grant date, vesting over four years. Curis develops cancer therapeutics, including collaborations on various treatments such as the IRAK4 inhibitor CA-4948, currently in clinical trials. This grant is intended to incentivize new hires and enhance employee retention.
Curis, Inc. (NASDAQ: CRIS) will be added to the Russell 2000®, 3000®, and Microcap® indexes, effective June 28, 2021. This inclusion recognizes Curis's market capitalization among the largest U.S. stocks, enhancing its visibility within the investment community. The Russell indexes serve as benchmarks for approximately $10.6 trillion in assets, indicating Curis's increased accessibility to institutional investors. CEO James Dentzer expressed enthusiasm for this milestone, highlighting the importance of index membership for overall growth and investor relations.
Curis, Inc. (NASDAQ: CRIS) announced positive updates from its Phase 1/2 trial of CA-4948, an IRAK4 kinase inhibitor, at the EHA 2021 Congress. The trial targets patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings show effective dose at 300 mg BID, with significant hematologic recovery and objective responses in patients with spliceosome or FLT3 mutations. CA-4948 also demonstrated synergistic activity in preclinical studies when combined with azacitidine and venetoclax. The company plans to initiate combination studies later this year.
Curis (NASDAQ: CRIS) announced a virtual KOL event on June 11, 2021, to discuss progress on CA-4948, a first-in-class IRAK4 kinase inhibitor. The event will include updated data from the Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), initially presented at the European Hematology Association 2021 Virtual Congress. Curis CEO James Dentzer and Dr. Guillermo Garcia-Manero from MD Anderson Cancer Center will lead the discussion, with a Q&A session to follow. A live webcast will be available on Curis' website.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?
Where can I find more information about Curis Inc.?
